PRENATALTEST screening is an absolutely accurate and reliable test to test DOWN T21 syndrome and other trisome-related disorders in chromosomes 13 and 18 (T13 T18). This molecular check (NIPT) evaluates beyond the embryo leaf (from the 10th week of pregnancy) and the possible diseases related to the number of X, Y chromosomes such as X, Y + Microdeletionsyndromes (** 9,16, ** 22 ** q11.2, 15 ** q11.2 1 ** p36.4 ** p and 5 ** p - **).

This method now comes to determine the risk of trisomy by measuring the relative amount of chromosomes of the fetus in the BABY AIMA, assessing the risk of trisomy 18, 21, 13 for the fetus, but not excluding all embryonic abnormalities. The truly revolutionary test first applied in the United States is based on the latest developments in modern molecular genetics and has been shown to be the most appropriate test for identifying the risk of specific trisomies with the predominance of trisomy 21.

The points of excellence of this method, with respect to previ- ous routine screening tests such as serum blood tests and ultrasound, may be non-invasive, but have false positives of up to 5% and non-detection rates of up to 30% of fetal trisomy 21. These tests may mistakenly assess a pregnancy as positive for embryonic trisomy while actually being normal. Invasive methods such as amniocentesis have a known risk of serious complications such as miscarriage, premature labor, infections, bleeding from a vaginal injury, or even fetal injury, which are now eliminated with PRENATALTEST.